Orion Oyj opens the week with a clear sector backdrop, shares on Nasdaq Helsinki watched against pharma peers

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-29, 13:16.

Orion Oyj (FI0009014377) remains a key pharma listing on Nasdaq Helsinki at the start of this week. The Finnish group last reported January–March 2026 figures in April, setting the tone for ongoing comparisons with peers such as Novo Nordisk and Bayer.Globenewswire interim report announcement

What the latest report showed

According to an April 10, 2026 release via Globenewswire, Orion said it would publish its Interim Report for January–March 2026 on April 23, 2026 around 12:00 noon EEST.Interim report scheduling release The company scheduled a webcast and conference call for analysts, investors and media at 14:00 EEST the same day, underlining its communication focus with institutional investors.Orion investor relations financials section

The interim report and related presentation materials were made available via Orion’s investor website after publication, offering detailed data on sales, operating profit and R&D spending.Orion investor relations homepage Contact for investor queries was listed as Investor Relations representative Tuukka Hirvonen, signaling a structured approach to market communication at the Helsinki-listed pharma group.IR contact details in April release

Sector context against European pharma

In sector terms, Orion operates alongside large European pharma names such as Novo Nordisk, Bayer and Roche, all active in prescription medicines and specialty therapies.Novo Nordisk investor relations Investors often compare margins, R&D intensity and pipeline visibility across these groups, with consensus data on operating margins and EPS growth published by brokers and aggregators such as MarketScreener.MarketScreener consensus overview for Orion

Recent commentary from European analysts on pharma has highlighted robust demand for chronic disease treatments and oncology drugs, with pricing discussions and reimbursement frameworks shaping earnings visibility.Reuters piece on European healthcare stocks In this context, Orion’s focus on proprietary brands and generics, alongside contract manufacturing, positions the Helsinki stock as a mid-cap exposure compared with larger S&P 500 pharma names.

The products behind Orion Oyj

Orion earns most of its revenue in human pharmaceuticals, including prescription medicines in neurology, oncology and cardiology, as well as proprietary brands and generic drugs.Orion corporate overview The company also has a presence in animal health products and engages in contract manufacturing for other pharma groups, diversifying its operating base.Human pharmaceuticals business description

Where the Orion Oyj shares trade today

The Orion Oyj shares (FI0009014377) trade on Nasdaq Helsinki, with the stock quoted in euros; the latest verified price data and market capitalization are available via the Helsinki exchange and Orion’s investor relations pages.

This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. All data and figures are based on sources believed to be reliable at the time of publication but may change without notice. Investors should conduct their own research or consult a qualified financial advisor before making investment decisions.